Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Patch delivered oxycodone into the blood stream in a reproducible, consistent and sustained manner
Subscribe to our email newsletter
Phosphagenics has reported successful completion of a phase 1 clinical study of its patented oxycodone transdermal matrix patch system. The results of the trial established that after a single dose, the patch delivered oxycodone into the blood stream in a reproducible, consistent and sustained manner.
Currently, the drug can only be administered orally or intravenously. Phosphagenics aims to offer chronic pain sufferers, such as cancer patients, an oxycodone gel or patch that will provide sustained pain relief.
Reportedly, the phase 1 trial results showed that the patch delivered approximately 40mg of oxycodone into the body over a 7-day period. Subjects were given a single dose of the drug using the company’s matrix patch which was removed three days after application.
Oxycodone delivery into the blood continued for four days after the patch was removed, demonstrating the depot effect of the company’s patented carrier system within the skin.
The trial was designed to assess the absorption profile of oxycodone in a matrix patch following a single administration, to acquire information necessary to obtain ethics approval for the repeat dose study.
The company said that the upcoming repeat dose study will be conducted on both the matrix and reservoir patch systems to determine the best patch for the phase 2 and 3 clinical trials.
Esra Ogru, chief operating officer said: “The oxycodone phase 1 trial was a very critical study for Phosphagenics demonstrating that our patch system could deliver oxycodone into the blood stream.
“We are very excited to be developing a treatment regime that will lead to therapeutic pain reduction and provide clinicians with more flexibility for treating patients. Our next trial, scheduled to be completed before the end of this year will involve a repeat daily dosing study and will examine oxycodone blood levels over a longer period. We are also in the final stages of submitting our US IND for our formulated oxycodone.”